Eisai

presented by
BioPharma, Pharma

Eisai Alzheimer’s Drug Data Show Slowing of Decline But Safety Questions Linger

Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.